EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy
- Design
- Guideline · None outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclearUNKNOWN: guidance for adults with MASH and liver fibrosis stages 2-3; no study population is described, and the condition is one the target population does not have.
- Could weight loss explain it?
- Not applicableNot applicable: a guidance document with no outcome data.
- Study tier
- Not ratedNOT_RATED: a joint society guideline without new primary data.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
European liver, diabetes and obesity societies issued joint guidance on using semaglutide (2.4 mg weekly by injection) or resmetirom in adults with MASH, an inflammatory fatty-liver disease. Drug treatment is recommended for non-cirrhotic MASH with fibrosis stages 2-3, with semaglutide possibly preferred for people with obesity, type 2 diabetes or cardiovascular disease. In MASH cirrhosis neither drug should be used as MASH-targeted treatment until liver benefits are shown. This is a recommendation document and reports no new study results.
01Findings
What the study reported
- Drugs
- Semaglutide
- Dose
- 2.4 mg sc weekly
- Route
- subcutaneous
- Comparator
- not reported in abstract
- Primary outcome
- recommendations on candidate selection, initiation, monitoring and discontinuation of resmetirom and semaglutide in MASH
- Effect
- not reported in abstract
- 95% confidence interval
- not reported in abstract
- Follow-up
- Not stated
- Adverse events
- Advises nutritional and sarcopenia assessment during semaglutide; in MASH cirrhosis resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment.
- Limitations
- Consensus guidance with no new primary data; the abstract notes that ongoing studies are still evaluating long-term effects on major adverse liver-related outcomes.
Who was studied
- Obesity status
- mixed (semaglutide may be preferred in adults with obesity; resmetirom in those without)
- Diabetes status
- mixed
- Cvd status
- mixed
- Ckd status
- mixed
- Baseline condition
- non-cirrhotic MASH with fibrosis stages 2-3
- Inclusion exclusion
- adults with non-cirrhotic MASH and fibrosis stages 2-3 by non-invasive tests or biopsy
Study quality details
- Study design
- Guideline / practice guidance
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- UNKNOWN
- Statistical precision
- no CI reported; guidance document
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The conflicts statement says only that declarations will be provided by the EASL CPG office; none are listed.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are at risk for cardiometabolic complications and major adverse liver-related outcomes (MALO), including cirrhosis, cancer, and liver transplantation. Non-invasive tests (NIT) for hepatic fibrosis, including vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or enhanced liver fibrosis (ELF) score, can replace liver biopsy to identify high risk for MALO (e.g. VCTE 10-20 kPa, MRE 3.1-5.0 kPa, or ELF 9.8-11.3), in which pharmacotherapy may be considered. Following approval by regulatory agencies, this joint EASL-EASD-EASO guidance provides updated recommendations for the use of resmetirom (80mg/100mg po) and semaglutide (2.4 mg sc weekly) in MASH, covering treatment candidate selection, treatment initiation, monitoring, and discontinuation. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimized comorbidity management. Therapy selection should be individualized according to preferences, potential risks, and cardio-renal-metabolic profile, including presence of obesity, type 2 diabetes (T2D), cardiovascular, and chronic kidney disease. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), may be preferred in adults with obesity or T2D as well as with established cardiovascular (CV) disease or high CV risk because of its cardiometabolic benefits, whereas resmetirom may be prioritized in individuals without obesity or those already receiving or intolerant to GLP-1RAs. Additional recommendations include structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria. Ongoing studies are evaluating long-term effectiveness of both agents to reduce MALO. In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 4, 2026 | 42805503 first ingestion |
| pubmed | Oct 4, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 4, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 4, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 4, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 4, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42805503 duplicate matched on doi |